Royce & Associates LP Sells 11,300 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Royce & Associates LP decreased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 3.0% during the fourth quarter, HoldingsChannel reports. The fund owned 362,819 shares of the biopharmaceutical company’s stock after selling 11,300 shares during the quarter. Royce & Associates LP’s holdings in Dynavax Technologies were worth $4,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC raised its holdings in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the period. GAMMA Investing LLC raised its holdings in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Dynavax Technologies during the 4th quarter valued at $71,000. Nisa Investment Advisors LLC grew its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Dynavax Technologies by 68.7% during the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,857 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Stock Down 1.9 %

Shares of NASDAQ:DVAX opened at $13.64 on Thursday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63. The firm has a fifty day moving average of $13.17 and a 200 day moving average of $12.36. The firm has a market capitalization of $1.69 billion, a PE ratio of 75.78 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. As a group, research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.